Form 4: Enanta CSO Or Yat Sun's Stock Award Vesting & Tax Forfeiture

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, reported the vesting of performance-based stock awards and subsequent share forfeiture for tax obligations.

Summary

• Chief Scientific Officer Or Yat Sun acquired 1,650 shares of Enanta common stock from vested Performance Share Units (PSUs).
• An additional 5,225 shares of Enanta common stock were acquired from vested relative Total Stockholder Return Units (rTSRUs).
• These awards vested on February 12, 2026, based on performance against two-year research and development milestones and relative total stockholder return.
• 3,413 shares were automatically forfeited at a price of $14.25 per share to cover withholding taxes related to the settlement of these awards.
• Following these transactions, Or Yat Sun beneficially owns 374,854 shares of Enanta common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting the routine vesting of performance-based compensation and standard tax withholding, rather than a discretionary trading decision by the insider.

Positives

• Vesting of 1,650 Performance Share Units (PSUs) indicates the achievement of two-year research and development milestones for the 2024-2025 period.
• Vesting of 5,225 relative Total Stockholder Return Units (rTSRUs) suggests Enanta's common stock performed favorably against the Nasdaq Biotech Index over a specified 60-day period.

Negatives

• 3,413 shares were forfeited at $14.25 per share to cover tax withholding obligations, reducing the net shares received from the awards.

Industry Context

StockSavvy.ai notes that performance-based equity awards, such as PSUs and rTSRUs, are common compensation tools in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance and shareholder value creation. The vesting of these awards suggests the company met specific internal R&D milestones and achieved competitive stock performance relative to its peers in the Nasdaq Biotech Index.

Stakeholder Impact

• Shareholders: The vesting of performance awards indicates the company met certain R&D and stock performance targets, which could be viewed positively.
• Reporting Person (Or Yat Sun): Increased direct ownership of company stock, aligning personal interests with long-term company performance, albeit with a portion forfeited for taxes.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, insider transaction, stock award, performance share units, PSU, rTSRU, relative total stockholder return, executive compensation, Chief Scientific Officer, Or Yat Sun, stock vesting, tax withholding